The role of vaccination in rabies prevention

Current Opinion in Virology

Volumn 2, Issue 3, 2012, Pages 309-314

  Briggs, Deborah J ^a  

^a Global Alliance for Rabies Control SA Non profit Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUCK EMBRYO CELL VACCINE; HUMAN DIPLOID CELL RABIES VACCINE; POLIOMYELITIS VACCINE; PURIFIED CHICK EMBRYO CELL VACCINE; PURIFIED DUCK EMBRYO CELL RABIES VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DISEASE SURVEILLANCE; DOG; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; MEDICAL EXPERT; MEDICAL HISTORY; MORTALITY; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; RABIES VIRUS; RESERVOIR; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SHELF LIFE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ANIMALS; DOG DISEASES; DOGS; HUMANS; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; VACCINATION;

EID: 84862837286     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.03.007     Document Type: Review

References (41)

1. Wu X, Smith TG, Rupprecht CE: From brain passage to cell adaptation: The road of human rabies vaccine development. Expert Rev Vaccines 2011, 10:1597-1608. The paper provides an extensive review on the history of human rabies vaccines beginning with the first rabies vaccine developed by Louis Pasteur and his colleagues in 1885. Details of the human rabies cell culture vaccines that are currently available including the seed strain of virus used for each type of vaccine and where the vaccines are licensed for use is explained. A brief description of the evolution of rabies vaccines over 120 and how the regimens for post-exposure prophylaxis have been reduced is included. Finally, the authors provide a commentary on the comparison of animal and human vaccines and stress the fact that the current human rabies vaccines have lagged behind the newer types of animal vaccines that are being produced using modern biotechnology.
2. Division of Environmental Health: http://www.doh.wa.gov/ehp/ts/ zoo/about.htm (updated January 2012) cited February 28, 2012.
3. Horsley V: On rabies: its treatment by m. Pasteur, and on the means of detecting it in suspected cases. Br Med J 1889, 1:342-344.
4. Baer GM: The history of rabies. In Rabies. Edited by Jackson AC, Wunner WH. Oxford: Elsevier, Inc.; 2007:1-22.
5. Burke DS: Joseph-Alexandre Auzias-Turenne, Louis Pasteur, and early concepts of virulence, attenuation, and vaccination. Perspect Biol Med 1996, 39:171-186.
6. Bahri F, Letaief A, Ernez M, Elouni J, Chekir T, Ben Ammou S, Jemni L: Neurological complications in adults following rabies vaccine prepared from animal brains. Presse Med 1996, 25:491-493. (Pubitemid 26111430)
7. Schneider MC, Santos-Burgoa C: Treatment of human rabies: a summary of its history. Rev Saude Publica 1994, 28:454-463.
8. Bonito RF, de Oliveira NM, Nishioka Sde A: Adverse reactions associated with a fuenzalida-palacios rabies vaccine: a quasi-experimental study. Rev Soc Bras Med Trop 2004, 37:7-9.
9. Who expert committee on rabies. World Health Organ Tech Rep Ser 1984, 709:1-104.
10. WHO: Who expert committee on rabies. World Health Organ Tech Rep Ser 1992, 824:1-84.
11. WHO: Who expert committee on rabies-second report. Can Med Assoc J 1954, 71:80.
12. Wiktor TJ, Koprowski H: Propagation of rabies virus in tissue culture. Monogr Ser World Health Organ 1966, 23:173-178.
13. Wiktor TJ, Fernandes MV, Koprowski H: Cultivation of rabies virus in human diploid cell strain wi-38. J Immunol 1964, 93:353-366.
14. Wiktor TJ, Plotkin SA, Grella DW: Human cell culture rabies vaccine. Antibody response in man. JAMA 1973, 224: 1170-1171.
15. Bahmanyar M, Fayaz A, Nour-Salehi S, Mohammadi M, Koprowski H: Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976, 236:2751-2754. (Pubitemid 8010765)
16. Aoki FY, Tyrrell DA, Hill LE: Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers. Lancet 1975, 1:660-662.
17. Fayaz A, Simani S, Nour-Salehi S, Bahmanyar M: Booster effect of human diploid cell antirabies vaccine in previously treated persons. JAMA 1981, 246:2334-2335.
18. Dreesen DW, Bernard KW, Parker RA, Deutsch AJ, Brown J: Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine. Vaccine 1986, 4:45-49. (Pubitemid 16129413)
19. Dreesen DW: Unavailability of human diploid cell rabies vaccine. J Am Vet Med Assoc 1984, 184:514.
20. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett SM, Levis R, Meltzer MI, Schaffner W, Cieslak PR: Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010, 59:1-9. This report updates the previous ACIP for PEP in humans, recommending a reduction in the five dose Essen regimen. Data are presented proving that four doses of rabies vaccine, given as one dose on each of days 0, 3, 7, and 14, are sufficient to produce a satisfactory immune response. At present, the new ACIP recommendations for the 4-dose PEP are exclusively for the US and follow the Essen schedule leaving out the fifth and final dose.
21. Dreesen DW, Fishbein DB, Kemp DT, Brown J: Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989, 7:397-400. (Pubitemid 19252621)
22. WHO: The immunological basis for immunization series. Rabies. Geneva: WHO; 2011:. pp. 1-23. The monograph provides an evidence-based review of the rational for rabies immunization schedules. The document includes information on longevity of immunity, booster recommendations, diagnostic testing information and data on the humoral and cellular immune response to vaccination.
23. Suntharasamai P, Warrell MJ, Warrell DA, Viravan C, Looareesuwan S, Supanaranond W, Chanthavanich P, Supapochana A, Tepsumethanon W, Pouradier-Duteil X: New purified vero-cell vaccine prevents rabies in patients bitten by rabid animals. Lancet 1986, 2:129-131. (Pubitemid 16098259)
24. Zhang X, Zhu Z, Wang C: Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose. Clin Vaccine Immunol 2011, 18:1477-1479.
25. World Health Organization: WHO Prequalified Vaccines. 2011 In: http://www.who.int/immunization-standards/vaccine-quality/rabies/en/ index.html/.
26. Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, Wiktor T, Koprowski H, Lecocq JP: Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984, 312:163-166. (Pubitemid 14000082)
27. Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, Kieny MP, Lathe R, Lecocq JP, Mackett M et al.: Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A 1984, 81:7194-7198. (Pubitemid 15216723)
28. Blancou J, Kieny MP, Lathe R, Lecocq JP, Pastoret PP, Soulebot JP, Desmettre P: Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 1986, 322:373-375. (Pubitemid 16098137)
29. Rupprecht CE, Wiktor TJ, Johnston DH, Hamir AN, Dietzschold B, Wunner WH, Glickman LT, Koprowski H: Oral immunization and protection of raccoons (procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci U S A 1986, 83:7947-7950. (Pubitemid 17183961)
30. Pastoret PP, Brochier B, Languet B, Thomas I, Paquot A, Bauduin B, Kieny MP, Lecocq JP, De Bruyn J, Costy F et al.: First field trial of fox vaccination against rabies using a vaccinia-rabies recombinant virus. Vet Rec 1988, 123:481-483. (Pubitemid 18267492)
31. Hanlon CA, Niezgoda M, Hamir AN, Schumacher C, Koprowski H, Rupprecht CE: First north american field release of a vacciniarabies glycoprotein recombinant virus. J Wildl Dis 1998, 34:228-239. (Pubitemid 128689322)
32. CDC: Compendium of animal rabies prevention and control. MMWR Recomm Rep 2011, 60:1-17.
33. Gerichter CB, Shtark J, Braunstein I: Clinical trial with an anti-rabies human diploid cell vaccine (hdcv). Dev Biol Stand 1978, 41:241-244. (Pubitemid 9104712)
34. Vodopija R, Lafont M, Baklaic Z, Ljubicic M, Svjetlicic M, Vodopija I: Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. Vaccine 1997, 15:571-574. (Pubitemid 27188625)
35. Vodopija I, Sureau P, Smerdel S, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M: Comparative study of two human diploid rabies vaccines administered with antirabies globulin. Vaccine 1988, 6:489-490. (Pubitemid 19002003)
36. Wasi C, Chaiprasithikul P, Thongcharoen P, Choomkasien P, Sirikawin S: Progress and achievement of rabies control in thailand. Vaccine (Suppl.):1997:S7-S11. (Pubitemid 27278172)
37. Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein D: Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1970, 335:3.
38. WHO: Report of a who consultation on the intradermal application of human rabies vaccines. Press Release 1985.
39. WHO expert consultation on rabies. World Health Organ Tech Rep Ser 2005, 931:1-88 (back cover).
40. Rabies, Countries or Areas at Risk. RabNet/Rabies Bulletin in Europe/Bulletin of Epidemiological Surveillance of Rabies in the Americas/Office International d'Epizooties; 2012.
41. Smith TG, Wu X, Franka R, Rupprecht CE: Design of future rabies biologics and antiviral drugs. Adv Virus Res 2011, 79:345-363. The paper details currently available rabies biologicals and stresses the need to develop new cost-effective biologicals. The need to review current methods used to develop rabies biologicals is indicated and it would be worthwhile to develop rabies vaccine strategies that would prevent rabies without the requirement to administer rabies immune globulin. The paper mentions the continued shortage of rabies immune globulins (RIGs) and the need to replace them with heterologous and homologous monoclonal antibodies. Additionally, the paper explains current research underway to find effective therapies for human rabies patients.